This article is more than 5 years old. Information may no longer be current.
Top stories in cardiology: sacubitril/valsartan for heart failure with preserved ejection fraction misses primary endpoint, cardiac fibrotic remodeling may be common in methamphetamine use
Among the top stories in cardiology last week were top-line results from the PARAGON-HF trial which showed that the trial narrowly missed statistical significance for the primary endpoint in patients with heart failure with preserved ejection fraction who were treated with sacubitril/valsartan and data that suggested patients who chronically used methamphetamine had maladaptive cardiac fibrotic remodeling which may be associated with mitochondrial dysfunction.
Other highlights included research that determined patients with diabetes or prediabetes who achieved at least five ideal CV health metrics did not have elevated risk for CVD events, a study that indicated pulse wave measurements independent of BMI and age was a good indicator of elevated CV risk in menopausal women and a study that found hormone therapy affected heart fat in women during menopause.
PARAGON-HF top-line results: sacubitril/valsartan for heart failure with preserved ejection fraction misses primary endpoint
Novartis announced top-line results from the PARAGON-HF trial, which showed that the trial narrowly missed statistical significance for the primary endpoint in patients with heart failure with preserved ejection fraction who were treated with sacubitril/valsartan compared with valsartan alone. Read more.
Cardiac fibrotic remodeling may be common in methamphetamine use
Patients who chronically used methamphetamine had maladaptive cardiac fibrotic remodeling which may be associated with mitochondrial dysfunction. Read more.
Patients with diabetes, ideal cardiovascular health have no excess CVD risk
Patients with diabetes or prediabetes who achieved at least five ideal CV health metrics did not have elevated risk for CVD events compared with people with normal glucose regulation, researchers reported. Read more.
Radial pulse wave may explain increased CV risk in menopausal women
Pulse wave measurements independent of BMI and age appear to be a good indicator of elevated CV risk in menopausal women. Read more.
Hormone therapy affects heart fat in women during menopause
Epicardial adipose tissue accumulation may slow down in women who were recently menopausal and were taking oral conjugated equine estrogens, according to a secondary analysis of the KEEPS trial published in the Journal of the American Heart Association. Read more.